Smith & Nephew (LON:SN) Stock Crosses Above 200 Day Moving Average – Should You Sell?

Smith & Nephew plc (LON:SN)’s share price passed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of GBX 1,057.99 ($13.72) and traded as high as GBX 1,165 ($15.11). Smith & Nephew shares last traded at GBX 1,141 ($14.80), with a volume of 2,833,536 shares traded.

Analysts Set New Price Targets

Separately, JPMorgan Chase & Co. restated an “overweight” rating and issued a GBX 1,180 ($15.30) price objective on shares of Smith & Nephew in a research report on Tuesday, January 14th.

Smith & Nephew Trading Down 1.8 %

The company has a debt-to-equity ratio of 70.22, a quick ratio of 0.84 and a current ratio of 2.51. The firm has a 50-day moving average of GBX 1,043.32 and a 200-day moving average of GBX 1,057.99. The firm has a market capitalization of £12.51 billion, a P/E ratio of 41.08, a price-to-earnings-growth ratio of 0.46 and a beta of 0.62.

Insider Transactions at Smith & Nephew

In related news, insider John Rogers acquired 71,920 shares of Smith & Nephew stock in a transaction on Thursday, December 19th. The shares were acquired at an average cost of GBX 972 ($12.61) per share, with a total value of £699,062.40 ($906,578.14). 0.19% of the stock is currently owned by company insiders.

Smith & Nephew Company Profile

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.